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Aim: To provide a systematic review, of published data, to compare weight losses 
following Very Low Calorie (<800kcal/day VLCD) or Low Energy Liquid-formula 
(>800kcal/day LELD) diets, in people with and without T2DM (T2DM). 
Methods: Medline Systematic electronic searches of Medline (1946-2015) and 
Embase (1947-2015) to identify published studies using formula Total Diet 
Replacement diets (VLCD/LELD).  Random effects meta-analysis using Weighted 
Mean Difference (WMD) in body weight between groups (with and without diabetes) 
as the summary estimate. 
Results: Final weight loss, in the 5 included studies, weighted for study sizes, 
(n=569, mean BMI=35.5-42.6kg/m2), was not significantly different between 
participants with and without T2DM : -1.2kg; 95%CI -4.1 to 1.6kg).  Rates of weight 
loss were also similar in the 2 groups -0.6kg/week (T2DM) and 0.5kg/week (no 
diabetes), and for VLCD (<800kcal/day) and LELD (>800kcal/day). 
 
Conclusions: Weight losses with liquid-formula diets are very similar for VLCD and 
LELD and for obese subjects with or without T2DM. They can potentially achieve 
new weight-loss/ maintenance targets of >15-20% for people with severe and 
medically complicated obesity.  
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Introduction 
As populations become more obese, there is increasing concern about the rapidly 
rising categories of severe obesity, which demand greater weight loss to control 
secondary medical consequences.  T2DM is closely linked to obesity, and is the 
main contributor to rising healthcare costs of obesity 1, 2.  Most individuals with T2DM 
have a BMI >25 kg/m2 and about half have a BMI >30 kg/m 2. 3, 4.  With a BMI over 
35 kg/m2, 20% of all men and 11% of women have known diabetes 5.   
There is overwhelming evidence that modest sustained weight loss, e.g. current 
target of 5-10%, prevents the onset of most new T2DM in people with pre-diabetes 6, 
and that it improves all aspects of diabetes control (glycaemia, blood pressure, lipids 
and microvascular damage 7 with reductions in drug doses for medications used to  
treat hypertension, diabetes and dyslipidaemia 8.,  While previous guidelines have 
retained a 5-10% weight-loss target, the 2010 Scottish Intercollegiate (SIGN) Obesity 
guideline, recognising changes in obesity prevalence, and also recent evidence for 
more aggressive interventions, has set a new national weight loss/maintenance 
target of >15-20% for those with BMI >35 kg/m, or >30 kg/m2 with serious medical 
complications such as T2DM 9.  In routine UK National Health Service diabetes care, 
few people achieve a weight loss of >15kg (or >15%).  Bariatric surgery is 
recommended for obese people with T2DM by both the UK National Institute for 
Care Excellence (NICE) 10 and SIGN 9, and has been shown to reverse the metabolic 
abnormalities of T2DM rapidly following surgery, at least in people up to 6 years after 
diagnosis of T2DM 11.  Surgery carries immediate and long-term risks, and is not 
acceptable to all people.  The metabolic benefits of bariatric surgery have been 
reproduced by negative energy balance alone, using a low energy liquid-formula 
diets, but these are seldom offered as part of diabetes care 12. 
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With conventional dietary advice, obese people with T2DM usually lose less weight 
than people without diabetes, partly because they have already lost what they can 
manage, and partly because many anti-diabetic drugs are obesogenic 13.   Here we 
provide a data synthesis, using systematic methods, assessing published studies to 
compare weight losses in people with T2DM and people without diabetes prescribed 
‘Total Diet Replacement’ using modern commercial nutrient-replete Very Low Calorie 
diets (VLCD, < 800kcal/d) or Low Energy Liquid formula diets (LELD, >800kcal/d).  
 
Methods 
This review was conducted following the PRISMA guidelines on systematic reviews 
14.  
Data sources and Searches 
Systematic electronic searches of Medline (1946-2015), Embase (1947-2015), and 
CINAHL (1946-2015) were performed to identify published studies using formula 
Total Diet Replacement diets.  Key search terms used were: (weight adj2 (loss or 
lost or losing or reduc* or change*)),*Obesity/; (type 2 diabetes or non-insulin-
dependent diabetic or non-insulin-dependent diabetes or type 2 diabetes mellitus); 
(low energy liquid diet or low energy diet or very-low calorie diet or liquid formula diet 
or calorie restriction or very low calorie diet).  Hand searching of reference lists of 
retrieved studies was also conducted. The search was limited to English language, 
human and adults.  
 
Study Selection 
Articles were selected on the basis of title and abstract.  Inclusion was dependent on 
the following eligibility criteria: non-randomised or randomised controlled trial with a 
Weight loss in obese patients with and without T2DM  
4 
 
primary purpose of weight management, adult participants (>18 years), weight 
change reported quantitatively, and a comparison of weight change in patients with 
and without T2DM made.  Identification of potentially relevant studies,  
Studies identified by the  
Database searches and review of potentially relevant studies against 
inclusion/exclusion criteria were carried out independently by two reviewers (WL & 
LH).  
 
Quality Assessment  
The quality and possible sources of bias of included studies was independently 
assessed by two reviewers (WL & LH) using the Cochrane Risk of Bias Assessment 
tool for Non-Randomised Studies of Interventions (ACROBAT-NRSI) 15. 
 
Data analysis 
A random effects meta-analysis was conducted using Comprehensive Meta-analysis 
(CMA; Version 3.0 for Windows).  The Weighted Mean Difference (WMD) in body 
weight between participants with T2DM and non-diabetic subjects was used as the 
summary estimate. Cochrane’s Q statistic was used to assess heterogeneity, with 
the I2 statistic used to measure the degree of heterogeneity. 
 
Because studies varied in duration, which necessarily affects total weight loss, a 
comparison was made between the rates of weight loss.  Mean weekly rate of weight 
loss was calculated for each study by dividing mean weight loss by number of study 
weeks.  Mean rate of weight loss for all studies was calculated by multiplying mean 
weekly weight loss for each study by number of study participants, and then the sum 
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of these figures was divided by the total number of participants in the group.  Where 
weight change was reported with SEM, this was converted to SD (SEM x √n) to 
provide consistency in the reported variability. 
Results 
The systematic search identified 151 potential studies. After duplicates were 
removed 121 titles and abstracts were screened. Obviously irrelevant studies were 
excluded for the reasons illustrated in Figure 1. Full texts of 17 studies were 
retrieved and reviewed for eligibility against the inclusion/exclusion.  Five studies 
fulfilled our criteria and were included in the review. 
 
Study Characteristics 
Setting 
The studies reported results from USA 16,17 Australia 18, UK 19, and Sweden 20.  The 
settings for studies varied. In one study the intervention was delivered on an 
inpatient basis 16, one was set in primary care 19 an endocrine clinic 18, obesity clinic 
17, and surgical unit 20. 
 
Participant demographics 
All studies recruited both males and females classified as obese (BMI >30kg/m2). 
One study (16) included some people with BMI >25kg/m2.  Mean age ranged from 43 
-55 years. 
 
Exclusion Criteria 
Exclusion criteria were not described in 2 studies 19 ,20.  Use of anti-obesity 
medications was an exclusion criterion in one study 18, and insulin use in another 16.  
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Medications 
Medications used in the management of T2DM were detailed in 3 studies 18,19, 20 and 
included metformin, sulphonylurea and insulin. The prescribed oral hypoglycaemic 
agents (OHA), was not specified in 1 study 16.  Medications in addition to those for 
diabetes management were detailed in two studies 18,19.  One study did not detail 
medications at all 17. 
 
Energy content and duration of formula diets and total diet replacement 
Daily energy provision from the formula diets varied among the included studies and 
ranged from 300 to 1000kcal/day (Table 1).  The durations of VLCD/LELD reported 
in studies ranged from 4 to 52 weeks.  In one study17 participants transitioned to 
include a meal of ~300 kcal at different time points.  
 
Quality of Included Studies 
All 5 included studies were non-randomised (as it is impossible to randomise into 
T2DM or non-diabetes categories); 2 case control studies 16, 17, 1 in which 
participants were allocated to the treatment of their preference 19, and 2 cohort 
studies; one retrospective 17 and one prospective 20.  As the studies were dietary 
interventions, none included blinding of participants.   
 
Confounding was considered the main possible source of potential moderate or 
serious bias in all included studies (Table 2).  Age, gender, baseline weight, and co-
morbid conditions are potential confounders in the achievement of weight loss.  Only 
one study included adjustments for these factors 17.  However in this study the 
transition from total meal replacement to partial meal replacement varied among 
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participants, with a potential influence on weight loss, and was not adjusted for in 
analysis.  Participant selection was considered unlikely to have introduced significant 
bias, as in all studies those with T2DM were compared to those without diabetes 
from the same or similar population.  Bias in the measurement of interventions was 
low, as in all studies the intervention was well defined.  Outcomes were ascertained 
using objective measurements in all studies and therefore the risk of bias was 
considered low. 
 
Attrition was reported in 2 of the 5 studies18 17, and weight change data were 
reported for completers only (excluding dropouts).  One study was carried out on an 
inpatient basis 16 and all subjects were included in weight change analyses  In one 
study 19 the study population was small, no dropouts were reported, and we have 
assumed all subjects were followed up and included in the analysis.   In the 
remaining study 20 all subjects completed the study and were included in the weight 
change analyses.  Risk of bias from missing data was therefore considered low. 
 
Weight Losses 
Baseline weights ranged from 99.0-126kg (BMI 30.0-42.6kg/m2).  Total weight loss 
ranged from 8.9 -15kg in those with T2DM and 7.9 -21kg in those without diabetes, 
over treatment durations of 4-52 weeks.   
 
The greatest rates of weight loss were mostly in studies with more restrictive VLCDs 
16, 19. Study duration did not appear to influence overall weight loss.  Mean weight 
loss in the study of longest duration 17 was similar, or greater, than that observed in 
studies of shorter duration (Table 1).  
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Meta-analysis 
Data allowing meta-analysis (mean weight change (SD or SEM)) were available for 4 
studies (Fig 2). Analysis showed almost identical weight changes (post intervention) 
in those with and without diabetes (Weighted Mean Difference: -1.2kg; 95%CI -4.1 to 
1.6kg).  Substantial heterogeneity was observed (I2= 79%).   
 
Safety 
Transient events including constipation, dizziness, postural hypotension, dry skin 
and bad breath were reported in 2 studies 16, 18.  Serious adverse events were 
reported in one study.  Severe hypoglycaemia was experienced by one diabetic 
patient using VLCD, and one patient in each group suffered a non-fatal myocardial 
infarction 19.  The remaining 2 studies reported that the intervention/study was 
completed without any adverse events 17, 20.   
 
Discussion 
Substantial mean weight losses were achieved in all studies following VLCD/LELD, 
varying from 8-21kg in total over 4-52 weeks.  That total depended on a variety of 
factors, including duration of diet, and clinical characteristics of groups, such as age, 
gender and status of health.  In all the studies, the mean rate of weight loss fell 
below that that predicted for 100% compliance with the estimated energy deficit.   
 
Weight losses were similar for participants with T2DM and participants without 
diabetes, with the exception of one study 16, where baseline weight was significantly 
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greater in participants without diabetes (126.1 ± 8.5 versus 99.7 ± 3.7 kg, P < 0.05), 
which is likely to have contributed to greater weight loss in the non-diabetic group.   
The data generated on weight loss per week, as studies varied widely in duration, 
also showed similar rates of weight loss in those with T2DM and those without. As 
with overall weight loss this was with the exception of the study by Henry 16, in which 
a greater rate of weight loss was observed in those without diabetes, again reflecting 
the higher baseline weight.  
 
The mean weight loss in people with T2DM reported here, in studies which 
compared people with T2DM and those without T2DM, is similar to a previous meta-
analysis of VLED in T2DM which reported substantial weight loss of 9.6% by people 
with T2DM over a 6 week period, at a rate of around 1.6 kg/week 13.  Studies using 
similar diets among only non-diabetic participants report similar mean weight losses 
21, 22, 23.   
Similar weight losses with VLCD &LELD have been reported previously n the study 
by Christensen 21, which compared VLCLD & LELD, with weight losses  of around 
11kg was observed in both study groups over 8 weeks.  Greater energy restriction 
also conferred no additional benefit in the study by Lin 22 with a mean weight loss of 
8 kg observed in both groups (450 vs.800 kcal/d) after 12 weeks.  Wikstrand and 
colleagues 23 reported mean weight losses of 20kg and 16kg in free living non-
diabetic, male and female participants respectively.   
 
Amongst the studies included in the present review, rates of weight loss were 
consistent, at 1.2-3.2 kg/week except for much lower rates in studies by Li 17 0.3 
kg/week, and Baker 18, 0.7 kg/week.  The study by Li was over a much longer period 
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of 52 weeks, and the duration of the exclusive formula diet phase was variable 
amongst participants over the 1 year period, as they could opt to include a meal of 
~300 kcal at different time points. which may have contributed to the lower rate of 
weight loss.  Lower weight loss in comparison to other studies was acknowledged by 
Baker and colleagues.  Factors suggested by the authors to explain this were a 
“calendar effect” and also that the study population were well established patients at 
a tertiary referral centre and may have represented a more “difficult to treat group” 
than that of other studies. 
 
The metabolic benefits of bariatric surgery appear to be reproducible by 
VLCD/LELD.  The Newcastle Counterpoint study 12 achieved reversal of T2DM with 
mean weight loss of 15.3kg in 11 people with T2DM within 4 years of diagnosis, 
using a 600 kcal/d low energy liquid diet.  The normalisation of fasting plasma 
glucose persisted for up to 3 months after return to normal diet.  Normalisation of 
HbA1c, or fasting blood glucose, following VLCD was reported in one study included 
in the present review 19, with mean absolute weight loss similar to that achieved by 
Lim and colleagues 12. However normalisation of metabolic status relates both to 
ongoing energy restriction and on overall weight loss.  Acute energy restriction has 
been shown to improve plasma glucose values and insulin sensitivity even before 
significant weight loss occurs 12,13.   
 
Formula diets, with a period of total diet replacement, are widely used and popular 
outside healthcare settings.  There is some published evidence that they are 
successful, with little or no evidence for serious safety problems 24 , although large-
scale safety testing has not been undertaken. The serious adverse events reported 
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in one study included in the present review were not considered directly related to 
the diet. Despite clear evidence for efficacy and lack of safety concerns, there is a 
continuing reluctance by medical staff and in clinical guidelines to support the use of 
formula diets.  Guidelines published in the USA and Australia25,26 advocate the use 
of very low calorie/energy diets for weight management, but recommend these 
should be delivered in medical settings, with close medical monitoring.   
At present formula diets are not funded directly within routine UK NHS care, whereas 
bariatric surgery is.  In the 1970s there was concern about safety of ill-designed 
modified fasting diets 27.  Beliefs that more intensive interventions and rapid weight 
loss lead to greater weight regain, are not supported by evidence from controlled 
trials.  Comparison of weight regains, following either a 12 week rapid weight loss 
programme or a 36 week gradual programme, found no difference in the proportion 
of weight regained at 144 week follow up 28.  Effective strategies for long-term 
weight-loss maintenance have been described 29,30.  A study conducted within 
routine NHS primary care 29 found that an 810 kcal/d Low Energy Liquid-formula Diet 
(LELD) was well accepted by 91 severely obese participants (mean BMI 48 kg/m2), 
and by GP’s and nurses. Those who attended had a mean weight loss of around 
17kg in 12 weeks.  Critically around 33% of all 91 entrants maintained >15kg weight 
loss at 12 months.  The study was in people without diabetes, but the present review 
would suggest that results in those with T2DM would not differ greatly.  One year 
follow up of patients with knee osteoarthritis also found that a structure found that a 
structured weight maintenance programme resulted in good maintenance of weight 
loss. 30 
It is estimated that by 2025, without new interventions for prevention of weight gain 
and obesity, five million people in the UK will have diabetes, mostly T2DM 
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(DiabetesUK.org).  Despite the recommendations in current clinical guidelines, there 
is no realistic prospect of bariatric surgery being offered to most obese people 
because of surgical and follow-up resource limitations.  In addition, many people will 
not agree to surgery.  New weight management approaches are required for obese 
people with T2DM that can be implemented in routine care, where most of these 
people are managed.  The present results suggest that the weight loss phase of 
weight management can be achieved by a period of ‘Total Diet Replacement’ TDR, 
using micronutrient-complete formula diets.  This approach towards the SIGN weight 
loss target of >15kg (enough to reverse most recent onset T2DM), in many cases is 
more cost-effectiveness than bariatric surgery29.   
Most published studies do not adequately describe whether adverse events were 
sought systematically, or simply reported on an ad-hoc basis.  Future research 
should include systematic data collection.  At present there is no evidence for 
serious adverse events, and no specific medical monitoring is necessary except for 
withdrawal or dose reduction of hypoglycaemic, diuretic or anti-hypertensive drugs.   
 
Limitations 
This systematic review was limited by the very small number of published studies, 
using a range of TDR methods, which directly compared weight losses in people with 
and without T2DM. There was substantial heterogeneity in the studies included, 
although due to the limited number of studies subgroup analysis could not be 
conducted to explore heterogeneity.  Differences in diets (ie. different calorie 
provisions across VLCD and LELD) and in particular the very different study 
durations probably explain much of the statistical heterogeneity.  We therefore 
expressed the results as kg lost per week, in order to reduce the effect of study 
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duration.  There was no clear pattern to suggest different rates of weight loss 
between VLED and LELD, despite different prescribed energy deficits, indicating 
differences in compliance. This supports the conclusion of Christensen et al that 
weight losses are similar on VLED or LELD 21.  Heterogeneity may also have arisen 
from differences in prescribed medications and other aspects of diabetes care 
between the studies included. Despite the heterogeneity, the results from the 
different studies remain rather similar both within and between the patient groups, 
which provides some confidence that there is no important difference in the weight 
loss responses of T2DM and non-diabetic people when treated with a formula ‘Total 
Diet Replacement’. Future studies should include more complete data on clinical 
details (e.g. medications) and complete data on the outcomes for all entered 
subjects. The extent of data among people with T2DM does not permit assessment 
of any diabetes-specific safety issues.  
Conclusion 
These data demonstrate that weight losses with VLCD or LELD are very similar, and 
that weight losses, following interventions of 4-52 weeks duration, are  no different 
for obese people with or without T2DM. This result is novel, since most published 
studies of diet and lifestyle interventions have shown less weight loss among 
subjects with diabetes.  It provides a firm baseline upon which the use of LELD may 
be further developed to achieve new weight-loss targets of >15-20% for those with 
severe and medically complicated obesity. Further research is warranted to evaluate 
the delivery of more intensive, and better sustained, non-surgical weight-
management approaches for routine NHS application, which could offer great benefit 
to people with T2DM.   
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Papers included in 
review (n=5) 
Papers excluded (n=12) 
Reasons: 
Review paper (1) 
Primary aim of study not weight 
management (1) 
VLCD/LELD used in one group 
only (3) 
No VLCD/LELD used (1) 
No comparison between patients 
with T2DM and those without (2) 
Study did not include patient with 
T2DM (2)  
Follow up of original study (2) 
 
Number of papers 
after removal of 
duplicates (121) 
Number papers 
screened (n=121) 
Id
e
n
ti
fi
c
a
ti
o
n
 
S
c
re
e
n
in
g
 
E
lig
ib
ili
ty
 
In
c
lu
d
e
d
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Table 1: Studies that directly compared weight loss using VLCD or LELD in patients with and without T2DM 
  
Mean age 
(SD) 
 
 
Sex 
(m/f %) 
 
Mean BMI at 
Baseline (kg/m
2 
   
Mean Weight Loss  
kg (SD) 
 
 
Mean weekly weight 
loss (kg) 
Reference n # Diabetic Non-
diabetic 
Diabetic Non-
diabetic 
Diabetic Non-
diabetic 
VLCD/LELD 
Duration 
(wk) 
Energy 
provision 
(kcal/d) 
Diabetic Non- 
diabetic 
Diabetic Non-
diabetic 
 
Noren
20 
(2014) 
 
Sweden 
 
 
25** 
 
48.8(8.3) 
 
N/A 
 
39.8 
 
4  
 
680 
 
(n=7) 
8.9(1.9) 
 
 
(n=18) 
7.9(2.8) 
 
2.2 
 
2.0 
 
Li
17 
(2014) 
 
USA 
 
444
* 
 
48.4 (10.0) 
 
 
44.3 (11.6) 
 
30/70 
 
23/77 
 
36.0 
 
34.7 
 
 
 
52 
 
 
500-1000 
 
(n=109) 
 
14.5(11.4) 
 
 
(n=337) 
 
14.5(11.8) 
 
0.3 
 
0.3 
 
Baker
18
 
(2012) 
 
Australia 
 
51* 
 
54.4 (7.3) 
 
48.5 (11.4) 
 
50/50 
 
33/67 
 
38.1 
 
36.6 
 
12 
 
800 
 
(n=24) 
 
8.5(6.3) 
 
 
(n=27) 
 
9.3(6.2) 
 
 
 
0.8 
 
0.7 
 
Paisey
19
 
(1998) 
 
UK 
 
34** 
 
50.3 (8.8) 
 
53.0 (5.5) 
 
47/53 
 
32/68 
 
30 
 
12-16 
 
Men  
540-570 
 
Women 
405-470 
 
 
(n=15) 
15 ≠ 
 
 
 
(n=19) 
21 ≠ 
 
 
 
1.2 
 
1.7 
 
Henry
16
 
(1986) 
 
USA 
 
15** 
 
49.9 (11.7) 
 
43.2 (3.5) 
 
20/80 
 
40/60 
 
35.5 
 
42.6 
 
5 
 
300 
 
(n=10) 
11.1 (2.2) 
 
 
(n=5) 
16.2 (2.4) 
 
 
2.2 
 
3.2 
 
Participant 
Total 
 
569 
 
  
Mean weekly rate of weight loss on VLCD/LELD 
(all studies combined weighted for numbers of subjects) 
 
 
0.6kg 
 
0.5kg 
# number used for analysis of weight change following VLCD/LELD; either * per protocol, or ** ITT ;≠ SD or SEM not reported
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Table 2: Risk of bias assessment 
 
Reference  
Risk of Bias 
Noren
 
 (2014)
 20
 Confounding: Serious risk 
Selection of participants: Low risk 
Measurement of interventions: Low risk 
Missing data: Low risk 
Measurement of Outcomes : Moderate risk  
 
Li (2014)
 17
 Confounding: Moderate risk 
Selection of participants: Low risk 
Measurement of interventions: Low risk 
Missing data: Low risk 
Measurement of Outcomes : Low risk  
 
 
Baker (2012)
 18
 
Confounding: Moderate risk 
Selection of participants: Low risk 
Measurement of interventions: Low risk 
Missing data: Low risk 
Measurement of Outcomes : Low risk 
  
 
Paisey (1998)
 19
 
Confounding: Serious risk 
Selection of participants: Moderate risk 
Measurement of interventions: Low risk 
Missing data: Low risk 
Measurement of Outcomes : Low risk  
 
 
Henry (1986)
 16
 
Confounding: Serious risk 
Selection of participants: No information 
Measurement of interventions: Low risk 
Missing data: Low risk 
Measurement of Outcomes : Low risk  
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